Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B
Top Cited Papers
Open Access
- 1 January 2018
- journal article
- research article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 6 (1), 1-10
- https://doi.org/10.14218/JCTH.2017.00073
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levelsHepatology, 2013
- High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation TherapyJournal of Clinical Gastroenterology, 2012
- Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patientsHepatology International, 2012
- Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CHepatology, 2011
- Prediction of the response to peg‐interferon‐alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatmentJournal of Medical Virology, 2010
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis BHepatology, 2008
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patientsHepatology, 2008
- Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment responseHepatology, 2006
- 50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis BJournal of Hepatology, 2006
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BThe New England Journal of Medicine, 2005